Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kindeva Completes Registration Batch at Aseptic Fill-Finish Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Kindeva Completes Registration Batch at Aseptic Fill-Finish Facility

Bridgeton, MO facility ready to provide injectable fill-finish capabilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Kindeva Drug Delivery, a global CDMO, has successfully completed its first registration batch on its groninger high-volume vial line at its state-of-the-art Bridgeton, MO facility, marking the facility’s readiness to provide injectable fill-finish capabilities.
 
Denis Johnson, Chief Operating Officer at Kindeva, said, “The completion of the first registration batch at the Bridgeton facility represents a significant milestone. This is the first of four lines planned to be installed in the next 18 months. Additionally, we are pleased to announce we have just successfully completed the Factory Acceptance Testing (FAT) on the first of two Optima syringe/cartridge filling lines planned for the new facility.”
 
The first Optima line is expected to arrive in November 2024, with qualification slated for completion in 1Q25. By the end of 2025, Kindeva anticipates both Optima lines will be fully qualified, enabling production capacity exceeding 100 million units annually across vials, cartridges, and syringes.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics